Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pulrodemstat in advanced solid tumors and NHL
NCT02875223Phase 1Terminated
- Sponsor
- Celgene Corporation
- Start
- Aug 2016
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 1, open-label trial of pulrodemstat in solid tumor, non-Hodgkin lymphoma (NHL), Neuroendocrine Neoplasm (NEN) and 2 more (3 arms), sponsored by Celgene Corporation. Primary endpoints: Number of Participants With Dose Limiting Toxicities and Maximum Tolerated Dose. Started Aug 2016; status: terminated.
02
Drugs
pulrodemstat
03
Conditions
solid tumornon-Hodgkin lymphoma (NHL)Neuroendocrine Neoplasm (NEN)neuroendocrine carcinoma (NEC)marginal zone lymphoma (MZL)
Beyond the preview
Go deeper on NCT02875223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02875223.